Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib Bioavailability and Food Effect Study
NCT06061523Phase 1Withdrawn
- Sponsor
- Amgen
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration of Sotorasib at 9 days, Area Under the Plasma Concentration-time Curve from Time Zero to Last Quantifiable Concentration at 9 days and 1 more. Planned start Jul 2024; status: withdrawn.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06061523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061523.